Medications

Shares of India's Ranbaxy slide 19% on new US FDA ban

Shares in one of India's biggest drugmakers, Ranbaxy Laboratories, slid 19 percent Friday after the US Food and Drug Administration suspended imports from a fourth manufacturing plant of the firm.

Medications

US drugs firm Mylan completes $1.75 bln India buyout

US generic drug specialist Mylan said Thursday it had completed its $1.75 billion acquisition of a unit of India's Strides Arcolab, boosting its presence in the high-growth injectable drugs market.

Other

Forest Labs plans to cut $500M in spending

Forest Laboratories says it plans to cut $500 million in costs in about two years, and also plans to buy back up to $1 billion in company stock.

Medications

US health watchdog curbs exports from India's Wockhardt

The US health regulator has restricted exports from a plant owned by Indian generic drugmaker Wockhardt in the latest ban on its products, sending the company's shares tumbling 14 percent on Wednesday.

Other

Indian drug giant Dr Reddy's Q2 profit up 69%

India's second-largest drugmaker Dr Reddy's Laboratories on Tuesday reported a 69.4 percent jump in quarterly net profit, as profit margins rose helped by improved sales.

page 12 from 14